{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-26-000029","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.920592+00:00","generated_at":"2026-05-15T08:30:02.154047+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results","bullets":["HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).","HI-PEITHO: No episodes of intracranial bleeding through 30 days; results published in NEJM.","CHAMPION-AF: WATCHMAN FLX showed 45% relative reduction in non-procedural major bleeding vs NOACs (10.9% vs 19.0%, P<0.001).","CHAMPION-AF: Primary efficacy endpoint met with non-inferiority to NOACs for stroke, CV death, or systemic embolism (5.7% vs 4.8%).","Both trials presented at ACC.26 and simultaneously published in The New England Journal of Medicine; data support expanded indications."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-26-000029","json":"https://secwatch.observer/filing/0000885725-26-000029.json","markdown":"https://secwatch.observer/filing/0000885725-26-000029.md","text":"https://secwatch.observer/filing/0000885725-26-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/0000885725-26-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/bsx-20260328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:30:02.154047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}